Vtesse, Inc. Forms Scientific Advisory Board
26-Mar-2015
- USA
Vtesse, Inc., a rare disease company focused on developing drugs for Niemann-Pick Disease Type C (NPC) and other severe diseases with great unmet need, announced the formation of its Scientific Advisory Board (SAB). Comprising experts from a range of fields including pediatrics, translational medicine, biomarker research and genetics, the SAB will advise on clinical and regulatory strategy as well as product development for the company's lead candidate, VTS-270.
Members of the Vtesse SAB include:
- Cristina Csimma , PharmD, MHP, Co-Chair, an established leader across the biopharmaceutical industry, venture capital and academic settings, and former founding chief executive officer of Cydan Development, Inc.
- Forbes D. Porter , MD, PhD, Co-Chair, a Senior Investigator and Program Head in the intramural research program of the Developmental Endocrinology and Genetics Program (PDEGEN) of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH), Principal Investigator for Phase I Clinical Trial of VTS-270
- Paul Gissen , MBChB, PhD, Professor, University College of London; Honorary Consultant in Paediatric Metabolic Diseases, Great Ormond Street Hospital; Wellcome Trust Senior Research Fellow in Clinical Sciences, University College London Institute of Child Health
- Marc C. Patterson , MD, FRACP, Chair, Division of Child and Adolescent Neurology; Professor of Neurology, Pediatrics and Medical Genetics, Mayo Clinic Children's Center, Rochester, MN
Other news from the department people
